FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4321437559> ?p ?o ?g. }

• W4321437559 endingPage "359" @default.
• W4321437559 startingPage "341" @default.
• W4321437559 abstract "Evolocumab, a fully human proprotein convertase/subtilisin kexin type 9 inhibitor antibody, significantly lowers low-density lipoprotein cholesterol (LDL-C) in patients with type 2 diabetes mellitus and hyperlipidemia and mixed dyslipidemia. This 12-week study evaluated the efficacy and safety of evolocumab in Chinese patients with primary hypercholesterolemia and mixed dyslipidemia at different levels of cardiovascular disease risk. HUA TUO was a 12-week randomized, double-blind, placebo-controlled study. Chinese patients aged 18 years or older on stable optimized statin therapy were randomized 2:2:1:1 to receive evolocumab 140 mg every 2 weeks (Q2W), evolocumab 420 mg monthly (QM), or a matching placebo. The coprimary endpoints were percent change from baseline in LDL-C at the mean of weeks 10 and 12 and at week 12. Overall, 241 randomized patients (mean [standard deviation] age, 60.2 [10.3] years) received evolocumab 140 mg Q2W (n = 79), evolocumab 420 mg QM (n = 80), placebo Q2W (n = 41), or placebo QM (n = 41). At weeks 10 and 12, the placebo-adjusted least-squares mean percent change from baseline in LDL-C for the evolocumab 140 mg Q2W group was − 70.7% (95% CI − 78.0% to − 63.5%); − 69.7% (95% CI − 76.5% to − 63.0%) for the evolocumab 420 mg QM group. Significant improvements in all other lipid parameters were observed with evolocumab. The patient incidence of treatment-emergent adverse events was similar between the treatment groups and across dosing regimens. In Chinese patients with primary hypercholesterolemia and mixed dyslipidemia, 12-week treatment with evolocumab significantly lowered LDL-C and other lipids, and was safe and well tolerated (NCT03433755)." @default.
• W4321437559 created "2023-02-22" @default.
• W4321437559 creator A5000620753 @default.
• W4321437559 creator A5015800351 @default.
• W4321437559 creator A5019344726 @default.
• W4321437559 creator A5024247850 @default.
• W4321437559 creator A5030978586 @default.
• W4321437559 creator A5034764782 @default.
• W4321437559 creator A5048660360 @default.
• W4321437559 creator A5052274869 @default.
• W4321437559 creator A5056647869 @default.
• W4321437559 creator A5077107136 @default.
• W4321437559 creator A5085150364 @default.
• W4321437559 creator A5090528056 @default.
• W4321437559 date "2023-02-21" @default.
• W4321437559 modified "2023-10-09" @default.
• W4321437559 title "Efficacy and Safety of Evolocumab in Chinese Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia: 12-Week Primary Results of the HUA TUO 华佗 Randomized Clinical Trial" @default.
• W4321437559 cites W1751918875 @default.
• W4321437559 cites W1971095820 @default.
• W4321437559 cites W2071155446 @default.
• W4321437559 cites W2093739200 @default.
• W4321437559 cites W2110496654 @default.
• W4321437559 cites W2121581403 @default.
• W4321437559 cites W2292665934 @default.
• W4321437559 cites W2400073014 @default.
• W4321437559 cites W2465758073 @default.
• W4321437559 cites W2474536315 @default.
• W4321437559 cites W2765581909 @default.
• W4321437559 cites W2785715927 @default.
• W4321437559 cites W2887473262 @default.
• W4321437559 cites W2900034165 @default.
• W4321437559 cites W2918318471 @default.
• W4321437559 cites W2921986630 @default.
• W4321437559 cites W2953804067 @default.
• W4321437559 cites W3004399337 @default.
• W4321437559 cites W3111060121 @default.
• W4321437559 cites W3113178943 @default.
• W4321437559 cites W3140799612 @default.
• W4321437559 cites W3161019480 @default.
• W4321437559 cites W3183857127 @default.
• W4321437559 doi "https://doi.org/10.1007/s40119-023-00304-x" @default.
• W4321437559 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36802321" @default.
• W4321437559 hasPublicationYear "2023" @default.
• W4321437559 type Work @default.
• W4321437559 citedByCount "0" @default.
• W4321437559 crossrefType "journal-article" @default.
• W4321437559 hasAuthorship W4321437559A5000620753 @default.
• W4321437559 hasAuthorship W4321437559A5015800351 @default.
• W4321437559 hasAuthorship W4321437559A5019344726 @default.
• W4321437559 hasAuthorship W4321437559A5024247850 @default.
• W4321437559 hasAuthorship W4321437559A5030978586 @default.
• W4321437559 hasAuthorship W4321437559A5034764782 @default.
• W4321437559 hasAuthorship W4321437559A5048660360 @default.
• W4321437559 hasAuthorship W4321437559A5052274869 @default.
• W4321437559 hasAuthorship W4321437559A5056647869 @default.
• W4321437559 hasAuthorship W4321437559A5077107136 @default.
• W4321437559 hasAuthorship W4321437559A5085150364 @default.
• W4321437559 hasAuthorship W4321437559A5090528056 @default.
• W4321437559 hasBestOaLocation W43214375591 @default.
• W4321437559 hasConcept C126322002 @default.
• W4321437559 hasConcept C142724271 @default.
• W4321437559 hasConcept C168563851 @default.
• W4321437559 hasConcept C197934379 @default.
• W4321437559 hasConcept C204787440 @default.
• W4321437559 hasConcept C27081682 @default.
• W4321437559 hasConcept C2776919658 @default.
• W4321437559 hasConcept C2778096610 @default.
• W4321437559 hasConcept C2778114629 @default.
• W4321437559 hasConcept C2778163477 @default.
• W4321437559 hasConcept C2778913445 @default.
• W4321437559 hasConcept C2779134260 @default.
• W4321437559 hasConcept C2780072125 @default.
• W4321437559 hasConcept C2780745583 @default.
• W4321437559 hasConcept C2780902209 @default.
• W4321437559 hasConcept C2780948078 @default.
• W4321437559 hasConcept C43554185 @default.
• W4321437559 hasConcept C71924100 @default.
• W4321437559 hasConcept C90924648 @default.
• W4321437559 hasConceptScore W4321437559C126322002 @default.
• W4321437559 hasConceptScore W4321437559C142724271 @default.
• W4321437559 hasConceptScore W4321437559C168563851 @default.
• W4321437559 hasConceptScore W4321437559C197934379 @default.
• W4321437559 hasConceptScore W4321437559C204787440 @default.
• W4321437559 hasConceptScore W4321437559C27081682 @default.
• W4321437559 hasConceptScore W4321437559C2776919658 @default.
• W4321437559 hasConceptScore W4321437559C2778096610 @default.
• W4321437559 hasConceptScore W4321437559C2778114629 @default.
• W4321437559 hasConceptScore W4321437559C2778163477 @default.
• W4321437559 hasConceptScore W4321437559C2778913445 @default.
• W4321437559 hasConceptScore W4321437559C2779134260 @default.
• W4321437559 hasConceptScore W4321437559C2780072125 @default.
• W4321437559 hasConceptScore W4321437559C2780745583 @default.
• W4321437559 hasConceptScore W4321437559C2780902209 @default.
• W4321437559 hasConceptScore W4321437559C2780948078 @default.
• W4321437559 hasConceptScore W4321437559C43554185 @default.
• W4321437559 hasConceptScore W4321437559C71924100 @default.
• W4321437559 hasConceptScore W4321437559C90924648 @default.
• W4321437559 hasFunder F4320307105 @default.

• next